Company Profile

Tosk Inc
Profile last edited on: 12/8/17      CAGE: 47WW1      UEI: M5DLPCVDRE95

Business Identifier: New drugs to block the adverse effects of existing cancer drugs
Year Founded
1998
First Award
2003
Latest Award
2018
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2672 Bayshore Pkwy Suite 507
Mountain View, CA 94043
   (408) 245-6838
   info@tosk.com
   www.tosk.com
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

With strong ties to work undertaken at Stanford, Tosk was founded to discover and develop new drugs for genetic diseases and cancer using non-mammalian animal species as models for human diseases. These efforts evolved into a proprietary drug discovery platform that uses the common fruit fly (Drosophila melanogaster) as a tool to discover new drugs. The company uses one application of this technology, known as OMD™ (Optimizing Marketed Drugs™) to discover adjuvants that reduce or eliminate the adverse effects of existing drugs. Tosk’s current drug discovery and development efforts focus on applying the OMD™ technology to discover cancer chemotherapeutic side-effect-reducing adjuvants. The first applications of the technology are for the widely used chemotherapeutics, methotrexate and doxorubicin. Tosk’s patented OMD™ technology uses Drosophila as a model to screen compounds for their potential to reduce or eliminate the adverse effects of existing drugs. The OMD™ technology enables Tosk to efficiently identify side-effect-reducing compounds that would be difficult and costly to discover using traditional methods. Tosk is also working on technology to discover drugs that block the action of cancer genes. This technology has the potential to identigy new drugs that make certain existing cancer drugs effective in patients who otherwise would not be able to benefit from the existi

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
25-49

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $2,224,872
Project Title: Screening with D. Melanogaster to Discover Inhibitors G12V Mutated kRAS
2010 1 NIH $199,500
Project Title: Anchored Antioxidants To Provide Increased Protective Effect
2003 1 NIH $93,400
Project Title: Gene delivery into whole, adult, large animals
2003 1 NIH $95,815
Project Title: Targeted gene delivery into whole, adult animals

Key People / Management

  Brian Frenzel -- President and CEO

  Harold Crow -- Chairman of the Board

  Patrick A Fogarty

  William A Garland -- Vice President, R&D

  Charles Garvin -- Director

  Stephen Yanofsky -- VP Research

Company News

There are no news available.